Phase-1 Trial: Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
RO7297089 is a bispecific tetravalent antibody targeting myeloma cells. In this MEDtalk, Fredrik Schjesvold, MD, PhD and the founder and leader of Oslo Myeloma Center at Oslo University Hospital, presents a phase I dose-escalation study, investigating the effect of RO7297089 in patients with RRMM. Results suggests a manageable safety but with lack of clinical efficacy with only two partial responses in 27 patients.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.